Literature DB >> 1838269

ASCO supports government report: "Off-label drugs: reimbursement policies constrain physicians in choice of cancer therapies".

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1838269

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  4 in total

1.  Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Authors:  Rena M Conti; Arielle C Bernstein; Victoria M Villaflor; Richard L Schilsky; Meredith B Rosenthal; Peter B Bach
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

2.  Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.

Authors:  Anne A Eaton; Camelia S Sima; Katherine S Panageas
Journal:  J Natl Compr Canc Netw       Date:  2016-01-05       Impact factor: 11.908

3.  Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.

Authors:  Weilan Wang; Man Zhu; Daihong Guo; Chao Chen; Dongxiao Wang; Fei Pei; Liang Ma
Journal:  Iran J Public Health       Date:  2013-05-01       Impact factor: 1.429

4.  The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.

Authors:  Marta Herrero Fernandez; Raquel Molina Villaverde; Monica Arroyo Yustos; Fatima Navarro Expósito; Jose Luis Lopez Gonzalez; Maria Rosario Luque Infantes; Melchor Alvarez-Mon Soto
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.